Engineered immune cells aim to stop bone Cancer's return in kids
NCT ID NCT07428993
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether a single infusion of B7-H3 CAR T cells, given after standard chemotherapy, can prevent the return of high-risk osteosarcoma in children. The study will enroll 41 participants who have completed upfront chemotherapy. Researchers will monitor how long participants stay cancer-free and track any side effects from the cell therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B7-H3 CAR T cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new way to prevent osteosarcoma from coming back after standard chemotherapy, potentially improving long-term survival for children with this aggressive cancer.
What could go wrong
This is a small, early-phase trial (41 participants) testing a complex cell therapy. It may not work for everyone, and there are risks of serious side effects like cytokine release syndrome or neurological problems. The long-term benefits are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105-2794, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact